Lunai Bioworks Inc. (LNAI) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-03-31..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-03-31..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-03-31..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-03-31..
Free cash flow
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-5.26M | Cash generated by operating activities. Period ending 2026-03-31. |
| Operating cash flow / net income · 12 months | 0.04× | Operating cash flow / net income. Period ending 2026-03-31. $-5.26M ÷ $-128.28M ≈ 0.04× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -5.26M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -128.28M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | (m) | $-5.26M | (m) | (m) | (m) | (m) | $-128.28M | (m) | (m) | (m) | 0.04× |
| 2025-12-31 | (m) | (m) | $-5.72M | (m) | (m) | (m) | (m) | $-125.52M | (m) | (m) | (m) | 0.05× |
| 2025-09-30 | (m) | (m) | $-7.21M | (m) | (m) | (m) | (m) | $-130.98M | (m) | (m) | (m) | 0.06× |
| 2025-06-30 | (m) | (m) | $-7.87M | (m) | (m) | (m) | (m) | $-178.01M | (m) | (m) | (m) | 0.04× |
| 2025-03-31 | (m) | (m) | $-8.48M | (m) | (m) | (m) | (m) | $-67.01M | (m) | (m) | (m) | 0.13× |
| 2024-12-31 | (m) | (m) | $-9.62M | (m) | (m) | (m) | (m) | $-126.19M | (m) | (m) | (m) | 0.08× |
| 2024-09-30 | (m) | (m) | $-10.21M | (m) | (m) | (m) | (m) | $-115.69M | (m) | (m) | (m) | 0.09× |
| 2024-06-30 | $-11.04M | (m) | $-10.97M | $70.43K | (m) | (m) | (m) | $-80.65M | (m) | (m) | (m) | 0.14× |
| 2024-03-31 | $-10.87M | (m) | $-10.82M | $53.02K | (m) | (m) | (m) | $-53.93M | (m) | (m) | (m) | 0.20× |
| 2023-12-31 | $-11.54M | (m) | $-11.49M | $47.73K | (m) | (m) | (m) | $-41.23M | (m) | (m) | (m) | 0.28× |
| 2023-09-30 | (m) | (m) | $-11.90M | (m) | (m) | (m) | (m) | $-41.16M | (m) | (m) | (m) | 0.29× |
| 2023-06-30 | $-11.80M | (m) | $-11.77M | $29.77K | (m) | (m) | (m) | $-39.68M | (m) | (m) | (m) | 0.30× |
| 2023-03-31 | $-12.59M | (m) | $-12.56M | $23.63K | (m) | (m) | (m) | $-106.72M | (m) | (m) | (m) | 0.12× |
| 2022-12-31 | $-12.06M | (m) | $-12.04M | $23.63K | (m) | (m) | (m) | $-108.60M | (m) | (m) | (m) | 0.11× |
| 2022-09-30 | (m) | (m) | $-13.28M | (m) | (m) | (m) | (m) | $-110.72M | (m) | (m) | (m) | 0.12× |
| 2022-06-30 | $-15.74M | (m) | $-15.73M | $5.16K | (m) | (m) | (m) | $-113.43M | (m) | (m) | (m) | 0.14× |
| 2022-03-31 | $-25.75M | (m) | $-25.71M | $43.33K | (m) | (m) | (m) | $-40.56M | (m) | (m) | (m) | 0.63× |
| 2021-12-31 | $-25.30M | (m) | $-25.26M | $43.33K | (m) | (m) | (m) | $-38.39M | (m) | (m) | (m) | 0.66× |
| 2021-09-30 | $-23.19M | (m) | $-23.13M | $54.05K | (m) | (m) | (m) | $-34.74M | (m) | (m) | (m) | 0.67× |
| 2021-06-30 | $-20.66M | (m) | $-20.61M | $48.89K | (m) | (m) | (m) | $-26.72M | (m) | (m) | (m) | 0.77× |
| 2021-03-31 | $-9.85M | (m) | $-9.83M | $21.17K | (m) | (m) | (m) | $-13.46M | (m) | (m) | (m) | 0.73× |
| 2020-12-31 | $-11.40M | (m) | $-11.34M | $62.86K | (m) | (m) | (m) | $-10.94M | (m) | (m) | (m) | 1.04× |
| 2020-09-30 | (m) | (m) | $-11.41M | (m) | (m) | (m) | (m) | $-9.73M | (m) | (m) | (m) | 1.17× |
| 2020-06-30 | $-10.64M | (m) | $-10.46M | $184.46K | (m) | (m) | (m) | $-11.42M | (m) | (m) | (m) | 0.92× |
| 2020-03-31 | $-10.59M | (m) | $-10.43M | $157.51K | (m) | (m) | (m) | $-6.15M | (m) | (m) | (m) | 1.70× |
| 2019-12-31 | $-9.54M | (m) | $-9.33M | $208.45K | (m) | (m) | (m) | $-7.36M | (m) | (m) | (m) | 1.27× |
| 2019-09-30 | $-8.99M | (m) | $-8.51M | $477.10K | (m) | (m) | (m) | $-21.75M | (m) | (m) | (m) | 0.39× |
| 2019-06-30 | $-9.22M | (m) | $-8.51M | $716.67K | (m) | (m) | (m) | $-18.02M | (m) | (m) | (m) | 0.47× |
| 2019-03-31 | $-8.63M | (m) | $-7.89M | $733.18K | (m) | (m) | (m) | $-29.89M | (m) | (m) | (m) | 0.26× |
| 2018-12-31 | (m) | (m) | $-6.89M | (m) | (m) | (m) | (m) | $-28.14M | (m) | (m) | (m) | 0.24× |
| 2018-09-30 | (m) | (m) | $-5.63M | (m) | (m) | (m) | (m) | $-11.23M | (m) | (m) | (m) | 0.50× |
| 2018-06-30 | $-4.37M | (m) | $-4.34M | $30.00K | (m) | (m) | (m) | $-9.15M | (m) | (m) | (m) | 0.47× |
| 2018-03-31 | (m) | (m) | $-3.23M | (m) | (m) | (m) | (m) | $-4.45M | (m) | (m) | (m) | 0.73× |
| 2017-12-31 | (m) | (m) | $-1.52M | (m) | (m) | (m) | (m) | $-1.73M | (m) | (m) | (m) | 0.88× |
| 2017-09-30 | (m) | (m) | $-1.36M | (m) | (m) | (m) | (m) | $-1.58M | (m) | (m) | (m) | 0.86× |
| 2017-06-30 | (m) | (m) | $-1.18M | (m) | (m) | (m) | (m) | $-2.14M | (m) | (m) | (m) | 0.55× |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $-1.04M | (m) | (m) | (m) | (m) | $-2.67M | (m) | (m) | (m) | 0.39× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $-1.47M | (m) | (m) | (m) | (m) | $-1.74M | (m) | (m) | (m) | 0.85× |
| 2016-03-31 | (m) | (m) | $-2.95M | (m) | (m) | (m) | (m) | $-2.40M | (m) | (m) | (m) | 1.23× |
| 2015-12-31 | (m) | (m) | $-4.91M | (m) | (m) | (m) | (m) | $-3.45M | (m) | (m) | (m) | 1.43× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $-5.22M | (m) | (m) | (m) | (m) | $-4.16M | (m) | (m) | (m) | 1.26× |
| 2015-03-31 | (m) | (m) | $-3.64M | (m) | (m) | (m) | (m) | $-3.20M | (m) | (m) | (m) | 1.14× |
| 2014-12-31 | (m) | (m) | $-2.03M | (m) | (m) | (m) | (m) | $-2.37M | (m) | (m) | (m) | 0.86× |
| 2014-09-30 | (m) | (m) | $-1.43M | (m) | (m) | (m) | (m) | $-2.45M | (m) | (m) | (m) | 0.58× |
| 2014-06-30 | (m) | (m) | $-1.47M | (m) | (m) | (m) | (m) | $-2.29M | (m) | (m) | (m) | 0.64× |
| 2014-03-31 | (m) | (m) | $-471.32K | (m) | (m) | (m) | (m) | $-454.01K | (m) | (m) | (m) | 1.04× |
| 2013-12-31 | (m) | (m) | $-35.99K | (m) | (m) | (m) | (m) | $-37.67K | (m) | (m) | (m) | 0.96× |
| 2013-09-30 | (m) | (m) | $-28.78K | (m) | (m) | (m) | (m) | $-38.84K | (m) | (m) | (m) | 0.74× |
| 2013-06-30 | (m) | (m) | $-26.12K | (m) | (m) | (m) | (m) | $-29.50K | (m) | (m) | (m) | 0.89× |
| 2013-03-31 | (m) | (m) | $-30.09K | (m) | (m) | (m) | (m) | $-37.59K | (m) | (m) | (m) | 0.80× |
| 2012-12-31 | (m) | (m) | $-32.47K | (m) | (m) | (m) | (m) | $-32.30K | (m) | (m) | (m) | 1.01× |
| 2012-09-30 | (m) | (m) | $-33.88K | (m) | (m) | (m) | (m) | $-33.83K | (m) | (m) | (m) | 1.00× |
| 2012-06-30 | (m) | (m) | $-31.75K | (m) | (m) | (m) | (m) | $-40.91K | (m) | (m) | (m) | 0.78× |
| 2012-03-31 | (m) | (m) | $-24.95K | (m) | (m) | $0.00 | (m) | $-29.95K | (m) | (m) | (m) | 0.83× |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |